Catalyst Brief

← Calendar

Readoutin 45d

Tolmar Inc. — TOL2506

Phase 3 primary completion: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer.

Date
Jan 2027
Type
Readout
Indication
Breast Cancer

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.